Kornimate/medical-research-clean huggingface dataset:
simple decompression versus anterior transposition of the ulnar nerve

Conditions: Humeral Fractures; Ulnar Nerve Compression

Summary: both simple decompression and anterior transposition of the elbow nerve (ulnar nerve) for acute displaced fractures of the elbow (distal humerus) treated with plate fixation are currently used by surgeons. we want to examine which treatment will overall give better results in regards to arm function and residual pain.


Eligibility criteria:
inclusion criteria: * men or women aged 16 to 60 years of age * displaced, distal humerus fracture (ota 13a or 13c) as seen in radiographs * fractures ≤ 28 days post injury * closed fractures * no history of previous ulnar neuropathy or elbow pathology * provisin of informed consent exclusion criteria: * vascular injury * history of previous ulnar neuropathy or elbow pathology * fractures more than 28 days post-injury * limited life expectancy due to significant medical co-morbidity or medical contraindication to surgery * inability to comply with rehabilitation or form completion * likely problems, in the judgement of the investigators, with maintaining follow-up (i.e. patients with no fixed address, patients not mentally competent to give consent, etc.)

Keywords: distal humerus fractures ulnar nerve simple decompression anterior transposition
adg126, adg126 in combination with anti pd1 antibody, and adg126 in combination with adg106 in advanced/metastatic solid tumors

Conditions: Advanced/Metastatic Solid Tumors

Summary: adg126, adg126 in combination with anti-pd1 antibody, and adg126 in combination with adg106 in patients with advanced/metastatic solid tumors .

adg126 is a novel anti-ctla-4 fully human igg1 antibody prodrug that is modified with adagene safebody technology to control the activation of anti-ctla4 activity.adg106 is a fully human ligand-blocking, agonistic anti-cd137 igg4 mab which is expected to enhance the activity of activated t cells. the enhanced antitumor efficacy results observed from the preclinical studies of adg126 in combination with adg106 or anti-pd-1 provided further support to explore such combinations in clinical settings for better patient responses.

Eligibility criteria:
inclusion criteria 1. adults ≥18 years of age. 2. ecog performance status 0 or 1. 3. estimated life expectancy of more than 12 weeks . 4. patients with advanced or metastatic solid tumors, confirmed by histologically or pathologically documented, who have progressed after all standard therapies, or for whom no further standard therapy exists. 5. at least 1 measurable lesion at baseline according to the definition of recist v1.1. 6. adequate organ function. 7. meets the additional tumor type requirements as specified in protocol. exclusion criteria: 1. treatment with any investigational drug within washout period. 2. major trauma or major surgery within 4 weeks prior to first dose of study drug(s) 3. history of significant immune-mediated ae. 4. central nervous system (cns) disease involvement. 5. prior organ allograft transplantations or allogeneic peripheral blood stem cell (pbsc)/bone marrow (bm) transplantation 6. clinically significant cardiac disease. 7. evidence of active uncontrolled viral, bacterial, or systemic fungal infection. 8. patients who received: 1. a covid-19 vaccine within 7 days of cycle 1 day 1. 2. live vaccines or live-attenuated vaccines within 28 days prior to cycle 1 day 1. 9. known active infection of hbv/bcv/hiv. 10. patients requiring systemic treatment with corticosteroids or other immunosuppressive medications (\>10 mg/day prednisone or equivalent). 11. second primary malignancy not in remission for greater than 3 years. 12. history(within the last 5 years) or risk of autoimmune disease. 13. pregnant or breastfeeding females. 14. childbearing potential who does not agree to the use of contraception during the treatment period.

Keywords: advanced/metastatic solid tumors
enabling independent living by expanding access to home-based pulmonary rehabilitation

Conditions: Chronic Obstructive Pulmonary Disease

Summary: the purpose of this study is to test an existing home-based pulmonary rehab program with the addition of video chat and a capability of a spanish version.

the purpose of this research is to test video chat on a computer tablet that is used for pulmonary rehabilitation. we are interested in learning patients' thoughts on how easy or difficult video chat is to use and the translation to spanish and the feed back from spanish speaking patients .

Eligibility criteria:
inclusion criteria: * patients must be ≥ 40 years old. * patients mist have a diagnosis of gold stage ii, iii, or iv copd documented by pulmonary function testing. * patients must be a current or previous smoker with at least 10 pack-years of cigarette smoking. additional inclusion criteria to test spanish version of system: * be a native spanish speaker. exclusion criteria: * patients with a high likelihood of being lost to follow-up or contact (patients with active chemical dependency). * patients planning to move out of the state or who are not living in the healthcare area. * patients with an inability to provide good data or follow commands (patients who are disoriented, have a severe neurologic or psychiatric condition).
safety and efficacy study of a new chemotherapy agent to treat non-small-cell lung cancer

Conditions: Carcinoma, Non Small Cell Lung

Summary: phase 2 study to investigate the efficacy and tolerability of epothilone zk 219477 in patients with stage iiib or stage iv non-small-cell lung cancer.

the study has previously been posted by schering ag, germany. schering ag, germany has been renamed to bayer schering pharma ag, germany.bayer schering pharma ag, germany is the sponsor of the trial.

Eligibility criteria:
inclusion criteria: * non-small-cell lung cancer * only one previous chemotherapy with a platinum-containing drug * use of highly effective birth control methods in females of child-bearing potential exclusion criteria: * no more than 1 previous chemotherapy for advanced disease * previous participation in another trial within the last 4 weeks * breast feeding * active infections

Keywords: stage iiib or stage iv non-small-cell lung cancer.
study to evaluate clinical efficacy and safety of bio mineral toothpaste in patients with mild periodontitis

Conditions: Periodontitis

Summary: the hypothesis of this study is that using "bio mineral" toothpaste for 4 weeks will decrease plaque and gingivitis of mild periodontitis patients compared to patients using "perio total care" toothpaste. this study is single blind, randomized, active-controlled comparative clinical trial to evaluate clinical efficacy and safety following the application for 4 weeks of bio mineral toothpaste in patients with mild periodontitis.

this study is single blind, randomized, active-controlled comparative clinical trial to evaluate clinical efficacy and safety following the application for 4 weeks of bio mineral toothpaste in patients with mild periodontitis. 30 patients of treatment group and 30 patients of control group, total 60 patients will be enrolled to this study. every patients will use investigational toothpaste 2 times everyday for 4 weeks and brush their teeth at least 3 minutes each time with 1ml of toothpaste.

Eligibility criteria:
inclusion criteria: 1. a healthy man or menopausal woman who is at least 18 to maximum 63 years of age. 2. agreed to participate voluntarily in the study. 3. must have over 20 maxillary teeth 4. must have mild periodontal disease which can induce mild plaque. 5. having no general disease except for dental disease. 6. must be able to understand and carry out the trial's objective and method. exclusion criteria: 1. who has history of using antimicrobials or antibiotics during the past 30 days. 2. who has history of periodontal treatment during the past 30 days. 3. who has acute pain or severe suppuration caused by pericoronitis of the wisdom tooth. 4. who has hypersensitive conditions caused by gingivitis or periodontitis. 5. who having restorative dentistry or wearing braces widely. 6. who using tobacco products (except for who quit smoking) 7. who has been participated in other clinical trials during the past 4 weeks. 8. who judged inappropriate to participate in the study by investigator

Keywords: mild periodontitis bio mineral toothpaste geumjin thermal water
causes and consequences of primary ovarian insufficiency

Conditions: Primary Ovarian Insufficiency; Premature Menopause

Summary: 100 women with primary ovarian insufficiency will be included for extensive diagnostic workup to improve diagnostic precision by extended autoantibody screening and genetic and toxicological testing.


Eligibility criteria:
inclusion criteria:women 40 years or younger, more than 4 months amenorrhea, more than 2 fsh measurements in menopausal range (drawn at least 2 months apart), ability to provide informed concent - exclusion criteria:history of oophorectomy, chemotherapy or radiation -
pully system exercise role in management of spasticity

Conditions: Cerebral Palsy

Summary: the goal of this clinical trial is to investigate the effect of pully system exercise in in management of spasticity in cerebral palsy children does pully system exercise has role in management of spasticity in cerebral palsy children ? participants will: the participants assigned to the control group will receive a standard care program. this program is designed to provide basic supportive therapies without the specialized pulley system exercises

there are two groups one group will receive traditional physical therapy programme another group will receive pully system exercise

Eligibility criteria:
inclusion criteria: * inclusion criteria * the degree of spasticity is (1) according to modified ashwarth's scale * they able to understand orders given to them. * all children evaluated before and after the suggested period of the physical therapy program (3months). exclusion criteria: * - no fixed deformities. * they have neither visual nor auditory problems. * they have neither perceptual nor cognitive problems.

Keywords: pully system cerebral palsy spasticity
the study will evaluate the effect of azd8683 in patients with chronic obstructive pulmonary disease (copd)

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Summary: the purpose of this study is to investigate effects of inhaled azd8683 compared to placebo in copd patients.

a double-blind, placebo-controlled, randomised, multi-centre, 3-way cross-over, single-dose phase ii study to investigate the local and systemic effects of inhaled azd8683 in patients with chronic obstructive pulmonary disease (copd)

Eligibility criteria:
inclusion criteria: * clinical diagnosis of copd * current or ex-smokers * fev1 40 - 80% of the predicted normal value (post-bronchodilator) and post-bronchodilator fev1/fvc \< 70% exclusion criteria: * any clinically significant disease or disorder * any clinically relevant abnormal findings at screening examinations * family history or presence of glaucoma * need of long term oxygen therapy

Keywords: chronic obstructive pulmonary disease (copd) safety inhalation long-acting muscarinic receptor antagonist (lama)
liposomal tretinoin in treating patients with recurrent or refractory hodgkin's disease

Conditions: Lymphoma

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. purpose: phase ii trial to study the effectiveness of liposomal tretinoin in treating patients who have recurrent or refractory hodgkin's disease.

objectives: i. determine the response rate, failure free survival, and progression free survival of patients with recurrent or refractory hodgkin's disease treated with tretinoin liposome. ii. determine the toxicities of this regimen in these patients. outline: this is a multicenter study. patients are stratified according to prior response to treatment (refractory vs recurrent vs post marrow transplant). patients receive tretinoin liposome iv over 30 minutes every other day for 28 days. treatment continues every 28 days for a total of 6 courses in the absence of disease progression or unacceptable toxicity. patients who are eligible for stem cell or marrow transplant receive at least 2 courses before crossing over to transplant. patients are followed every 3 months. projected accrual: a total of 105 patients (35 per strata) will be accrued for this study over 2-3 years.

Eligibility criteria:
disease characteristics: histologically confirmed recurrent or refractory hodgkin's disease recurrent after partial or complete response after initial therapy or refractory after no response or progression after initial therapy at least 2 prior treatment regimens (radiotherapy considered separate if not part of planned combined modality) bidimensionally measurable disease no active cns disease patient characteristics: age: 12 and over performance status: zubrod 0-2 life expectancy: not specified hematopoietic: absolute neutrophil count at least 500/mm3 platelet count at least 20,000/mm3 hepatic: bilirubin no greater than 1.5 mg/dl sgpt less than 4 times upper limit of normal renal: creatinine no greater than 3.0 mg/dl other: not pregnant or nursing fertile patients must use effective contraception must not be eligible or willing to undergo treatment of a higher priority hiv negative no other prior malignancies within the last 5 years except basal cell carcinoma of the skin or carcinoma in situ of the cervix treated with curative intent no other concurrent serious illness or active infection no mental or social reasons that may preclude study prior concurrent therapy: biologic therapy: no more than 1 prior autologous stem cell or marrow transplant no prior allogenic stem cell or marrow transplant chemotherapy: see disease characteristics must be recovered from last regimen no prior retinoids, including tretinoin endocrine therapy: no concurrent steroids radiotherapy: see disease characteristics must be recovered from last regimen surgery: not specified

Keywords: recurrent adult hodgkin lymphoma recurrent/refractory childhood hodgkin lymphoma
non-invasive ctdna methylation detection for lung nodule patients

Conditions: Lung Nodule

Summary: low-dose computed tomography (ldct) is recommended for early-stage lung cancer screening. however, it is often difficult to determine indolent lesions from more aggressive tumors without an invasive intervention or prolonged follow-up period. thus, the main purpose of this study is to develop a non-invasive method to detect lung-cancer specific circulating tumor dna (ctdna) in blood, which can greatly improve the specificity of lung cancer early screening.

in this study, the investigators sought to explore sensitive and specific methylation biomarkers that are highly prevalent in lung cancer. it is the first time to perform screening assay on healthy, lung nodule, and lung cancer tissues to identify preliminary set of highly prevalent methylation markers, and then refined these markers by removing regions were unstable in matched plasma samples. next, investigators interrogated significant methylation marker regions enriched in lung nodules of training sample set to buildup a non-invasive biomarker classification model to discriminate cancerous nodules from benign lesions. eventually, the model in patient lung nodule samples were validated.

Eligibility criteria:
inclusion criteria: 1. 18 years old or above with pulmonary nodule(s) found by ldct, mean diameter below 30mm. 2. the nodule lesion is peripheral, no signs of lymphatic infiltration or distal metastasis. 3. fit and consent to surgical resection. 4. agree to participate in this study and sign informed consents. exclusion criteria: 1. fail to understand or agree to sign informed consent. 2. patients who did not follow the test plan for timely blood collection or did not cooperate with the study follow-up work. 3. patients with previous history of cancer and/or cancer treatment such as surgery, radiotherapy, chemotherapy or targeted therapy. 4. failing to meet the requirements for blood sampling.

Keywords: dna methylation ctdna
laughter yoga effect on cancer patients' physiopsychological symptoms

Conditions: Cancer; Nurse's Role; Quality of Life

Summary: the universe of this study will consist of cancer patients and their relatives who are hospitalized in the medical oncology clinic of atatürk university research and practice hospital between oct 2024 and feb 2024. the researcher will stratify the patients in the control and intervention groups according to age and the type of treatment they receive in order to ensure homogeneity. accordingly, the patient in each stratum will be selected from one of the labels prepared in a bag with the words "experimental" and "control" written on it and the patient will be included in the group written on the label. the patients in the control and intervention groups will not know which group they are in, but only the researcher will know who is in which group. in this way, blinding will be ensured and the study will be completed as single-blind.

sample size calculation: the minimum number of people to be included in the sample was calculated by performing a power analysis. using the "g.power-3.1.7" program, the sample size was calculated with a test power of 0.80. as a result of the power analysis, it was determined that a total of 60 patients should be included in the control and intervention groups at α=0.05 level and 80% power. the patients to be included in the study will be randomized and assigned to the intervention (n=30) and control (n=30) groups. volunteer acceptance for the study will begin after the acceptance of the study within the created work packages. data collection tools: the data of the study will be collected in the experimental and control groups using the "personal information form", "edmonton symptom assesment scale", "herth hope scale" and "life engagement scale". criteria for volunteers to be included in the study: 1. being 18 years of age or older 2. being diagnosed with cancer and having knowledge about the disease 3. not having a physical illness or cognitive disability that would prevent understanding the scales used for data collection and the education provided, and not having a psychiatric illness diagnosis 4. being literate 5. being open to communication and collaboration

Eligibility criteria:
inclusion criteria: 1. being 18 years of age or older 2. being diagnosed with cancer and having knowledge about the disease 3. not having a physical illness or cognitive disability that would prevent understanding the scales used for data collection and the education provided, and not having a psychiatric illness diagnosis 4. being literate 5. being open to communication and collaboration exclusion criteria: 1. being under 18 years of age 2. not having information about the disease 3. having a physical illness or cognitive disability that prevents understanding the scales used for data collection and the education given, and being diagnosed with a psychiatric disease 4. being illiterate 5. not being open to communication and cooperation
study of orl-1m (d-mannose) in patients with cdg-ib

Conditions: CDG Ib

Summary: study of orl-1m in patients with cdg-ib


Eligibility criteria:
inclusion criteria: * diagnosis of cgd-1b. * less than 18 years old. exclusion criteria: * diagnosis of any other disease that is not a manifestation of cgd-1b.

Keywords: cdgib mannosephosphate isomerase deficiency mpi deficiency protein-losing enteropathy-hepatic fibrosis syndrome saguenay-lac saint-jean syndrome slsj syndrome
comparison of efficacy between ilm forceps

Conditions: Macular Holes; Epiretinal Membrane

Summary: this study is a single center, prospective, observational, multi surgeon randomized controlled trial. subjects will be assessed pre-operatively, operatively and at 1 month postoperatively. clinical evaluations will include measurement of visual acuity and optical coherence tomography (oct).


Eligibility criteria:
inclusion criteria: • 19y and older patients with symptomatic erm (grade 2-3) or macular hole (non flap-requiring) for elective ilm peeling surgery. exclusion criteria: * co-morbid diabetic retinopathy of any grade. * neovascular amd. * previous vitrectomy. * previous retinal detachment treated with scleral buckle or pneumatic retinopexy. * uncontrolled glaucoma or previous glaucoma surgery. * combined phacovitrectomy. * macula holes with severity requiring flap.
evaluating the potential of large language models for respiratory disease consultations

Conditions: Hay Fever; Asthma; Acute Upper Respiratory Infection; Pulmonary Embolism; Pneumonia; Tuberculosis; Acute Bronchitis; Pulmonary Fibrosis; Lung Cancer; Bronchiectasis

Summary: the clinical trial aimes to evaluate multiple large language models in respiratory disease consultations by comparing their performance to that of human doctors across three major medical consultation scenarios. the main question aims to answer are: * how do large language models perform in comparison to human doctors in diagnosing and consulting on respiratory diseases across various clinical scenarios? in three clinical scenarios including the online query section, the disease diagnosis section and the medical explanation section, research assistants or volunteers will be asked to cross-question all llms or real doctors using predefined online questions and their own issues. after each questioning session, a short washout period is implemented to eliminate potential biases.


Eligibility criteria:
inclusion criteria: 1. self-reported symptoms of common respiratory diseases, such as cough, chest tightness, fever, and wheezing 2. ability to engage in llm dialog operations independently or with minimal peer training 3. a health status deemed suitable for study participation by the pulmonology experts exclusion criteria: 1) excessively poor health status
intrathecal therapy for chronic non-cancer pain: an analysis of its efficacy

Conditions: Chronic Pain

Summary: our hypothesis is that patients with intrathecal delivery systems for chronic non-cancer pain will report no improvement treatment efficacy when compared to patients with chronic pain managed with oral or systemic opioid therapies. our secondary hypothesis is that patients with intrathecal delivery systems for chronic non-cancer pain will report no improvement in treatment efficacy when compared to patients with chronic pain who are managed with non-opioid therapies.


Eligibility criteria:
inclusion criteria: * males or females greater than 18 years of age with legal decision making ability. * subjects receiving care at the brigham and women's hospital pain management center. * subjects must have a history of chronic pain \> 6 months and must have been a patient in the bwh pain center \> 6 months. exclusion criteria: * pain due to metastatic cancer or to cancer that is locally invasive * patients with a primary diagnosis of spasticity, receiving intrathecal baclofen * evidence of psychosis or hospitalization for psychiatric illness during study * pregnancy at any time during the study * altered mental status that would make subject unable to complete outcome questionnaires * significant chronic medical illness, such that requires frequent hospitalization or health care utilization (ie: renal failure requiring dialysis, heart failure or cardiac disease requiring surgery or intensive care admission, pulmonary disease requiring intubation or hospitalization, pancreatitis requiring hospitalization, vascular disease requiring surgery or hospitalization, etc.)

Keywords: chronic pain intrathecal pain management